NEW MICROBES DISCOVERED IN FEATHERS

LAURA COX | August 13, 2019 | 75 views

Deep beneath the sea, in the East Pacific Ocean, a new species of bacteria has been discovered in sediment from over 3,700 metres below the surface. This new microbe produces bright yellow colonies when grown in the lab and was named Chengkuizengella marina.

Spotlight

R10MEDICINE

R10MEDICINE is an innovative new community for aspiring physicians and physicians aimed at exploring new solutions to the growing problems in the medical profession and in healthcare. Any medical student, graduate, or physician from anywhere can join. Members have access to a myriad of programs, benefits, and opportunities found exclusively here.

OTHER ARTICLES
RESEARCH

Top 10 biotech IPOs in 2019

Article | July 11, 2022

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More
MEDTECH

Cell Out? Lysate-Based Expression an Option for Personalized Meds

Article | October 7, 2022

Cell-free expression (CFE) is the practice of making a protein without using a living cell. In contrast with cell line-based methods, production is achieved using a fluid containing biological components extracted from a cell, i.e., a lysate. CFE offers potential advantages for biopharma according to Philip Probert, PhD, a senior scientist at the Centre for Process Innovation in the U.K.

Read More
MEDTECH

Closing bacterial genomes from the human gut microbiome using long-read sequencing

Article | July 20, 2022

In our lab, we focus on the impact of the gut microbiome on human health and disease. To evaluate this relationship, it’s important to understand the particular functions that different bacteria have. As bacteria are able to exchange, duplicate, and rearrange their genes in ways that directly affect their phenotypes, complete bacterial genomes assembled directly from human samples are essential to understand the strain variation and potential functions of the bacteria we host. Advances in the microbiome space have allowed for the de novo assembly of microbial genomes directly from metagenomes via short-read sequencing, assembly of reads into contigs, and binning of contigs into putative genome drafts. This is advantageous because it allows us to discover microbes without culturing them, directly from human samples and without reference databases. In the past year, there have been a number of tour de force efforts to broadly characterize the human gut microbiota through the creation of such metagenome-assembled genomes (MAGs)[1–4]. These works have produced hundreds of thousands of microbial genomes that vastly increase our understanding of the human gut. However, challenges in the assembly of short reads has limited our ability to correctly assemble repeated genomic elements and place them into genomic context. Thus, existing MAGs are often fragmented and do not include mobile genetic elements, 16S rRNA sequences, and other elements that are repeated or have high identity within and across bacterial genomes.

Read More

Selexis Cell Line Development Strategies

Article | February 11, 2020

In today’s biotechnology landscape, to be competitive, meet regulations, and achieve market demands, “we must apply Bioprocessing 4.0,” said Igor Fisch, PhD, CEO, Selexis. In fact, in the last decade, “Selexis has evolved from cloning by limiting dilution to automated cell selection to nanofluidic chips and from monoclonality assessment by statistical calculation to proprietary bioinformatic analysis,” he added. Single-use processing systems are an expanding part of the biomanufacturing world; as such, they are a major component of Bioprocessing 4.0. “At Selexis, we use single use throughout our cell line development workflow. Currently, we have incorporated single-use automated bioprocessing systems such as ambr® and the Beacon® optofluidic platform for accelerated cell line development. By using these systems and optimizing our parameters, we were able to achieve high titers in shake flasks. Additionally, the Beacon systems integrate miniaturized cell culture with high-throughput liquid handling automation and cell imaging. This allows us to control, adjust, and monitor programs at the same time,” noted Fisch.

Read More

Spotlight

R10MEDICINE

R10MEDICINE is an innovative new community for aspiring physicians and physicians aimed at exploring new solutions to the growing problems in the medical profession and in healthcare. Any medical student, graduate, or physician from anywhere can join. Members have access to a myriad of programs, benefits, and opportunities found exclusively here.

Related News

Scientists Turn Crop Waste into Fragrances with Microbes

Labiotech.eu | November 27, 2019

In a study published in the journal Green Chemistry, the scientists used engineered Escherichia coli bacteria to break down sugar cane and wheat straw, waste products from the agricultural industry. The bacteria then fermented the waste materials into coniferol, a high-value chemical used in fragrances and washing powders. The research was carried out by scientists based at the Manchester Institute of Biotechnology, University of Manchester, UK, and two universities in Brazil. At present, chemicals and fuels used in many industries are derived from fossil fuels, a finite resource. There are growing industries dedicated to obtaining these products from more renewable and cleaner sources, such as making biofuels from crops. However, it is hard for biofuels to compete economically with the fossil fuel industry because the latter often has more established technologies. To get around this issue, the research team has developed fermentation technology to cheaply turn plant waste into coniferol, a chemical that is more valuable than biofuels. The team is now preparing to scale up the process and is also working to overcome challenges in the technology. These challenges include making sure that the engineered E. coli bacteria remain able to process the plant waste over many generations.

Read More

Scientists Turn Crop Waste into Fragrances with Microbes

Labiotech.eu | November 27, 2019

In a study published in the journal Green Chemistry, the scientists used engineered Escherichia coli bacteria to break down sugar cane and wheat straw, waste products from the agricultural industry. The bacteria then fermented the waste materials into coniferol, a high-value chemical used in fragrances and washing powders. The research was carried out by scientists based at the Manchester Institute of Biotechnology, University of Manchester, UK, and two universities in Brazil. At present, chemicals and fuels used in many industries are derived from fossil fuels, a finite resource. There are growing industries dedicated to obtaining these products from more renewable and cleaner sources, such as making biofuels from crops. However, it is hard for biofuels to compete economically with the fossil fuel industry because the latter often has more established technologies. To get around this issue, the research team has developed fermentation technology to cheaply turn plant waste into coniferol, a chemical that is more valuable than biofuels. The team is now preparing to scale up the process and is also working to overcome challenges in the technology. These challenges include making sure that the engineered E. coli bacteria remain able to process the plant waste over many generations.

Read More

Events